News

Eli Lilly: Don't Bet Against This Biotech Powerhouse

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly and Company (LLY) Releases Q2 2025 Results

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...

This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors

Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

3 Fantastic Growth Stocks to Buy in August

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

1 Beaten-Down Stock That Could Soar by the End of the Year

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Notable healthcare headlines for the week: UnitedHealth, Eli Lilly, Pfizer in focus

Wall Street’s major averages ended mostly lower on Friday, as market participants have been keeping an eye on the highly anticipated meeting between Donald Trump and Vladimir Putin. However, the S&P ...